Home » Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Neuralstem, Inc. announced that the FDA has approved its investigational new drug application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) with its spinal cord stem cells.
Yahoo! Finance
Yahoo! Finance
Upcoming Events
-
07May
-
14May
-
30May